Bendamustine HCL for the treatment of relapsed indolent non-Hodgkin’s lymphoma

Figures & data

Figure 1 Structure of bendamustine.

Table 1 Bendamustine in combination with other cytotoxic substances

Author	Bendamustine plus	N	ORR (%)	CR (%)	PR(%)
Ruffert et al (1989)	Vincistine + prednisone	31	90	38	52
Blumenstengel et al (1998)	Vincristine + prednisone	22	86	45	41
Herold et al (1999)	Vincristine + prednisone	82	66	22	44
Kath et al (2000)	Vincristine + prednisone	22	86	45	41
Heck et al (1998)	Mitoxantrone	29	59	7	52
Kahl et al (1997)	Mitoxantrone + MTX + prednisone	23	48	13	35
König et al (1999)	Dexamethasone + idarubicine	14	79	29	50
Ruffert (1999)	Etoposide orally	38	97	67	30
Königsmann et al (2004)	Fludarabine	29	77	45	32

Abbreviations: MTX, methotrexate; CR, complete remission; ORR, overal response rate; PR, partial remission.

Table 2 Bendamustine in combination with rituximab

Author	Bendamustine plus	N	ORR(%)	CR(%)	PR(%)
Kirchner et al (2001)	Fludarabine + rituximab	25	76	28	48
Weide et al (2004)	Mitoxantrone + rituximab	54	96	41	55
Rummel et al (2005)	Rituximab	63	90	60	30
Robinson et al (2005)	Rituximab	54	84	21	63
Van der Jagt et al (2006)	Rituximab	66	94	41	53
Weide et al (2007)	Mitoxantrone + rituximab	57	89	35	54

Abbreviations: CR, complete remission; ORR, overal response rate; PR, partial remission.

RuffertKJannHSyrbeG1989Cytostasan (bendamustine) as an alternative therapeutic approach to treat malignant non-Hodgkin’s lymphomaZ Klin Med446714

 Google Scholar

BlumenstengelKFrickeHJKathR1998Bendamustine (B), vincristine (O), prednisone (P) in relapsed and refractory low grade non-Hodgkin’s lymphoma (NHL) [abstract]Ann Hematol77Suppl 11S149

 PubMedGoogle Scholar

HeroldMSchulzeAMantovaniL1999BOP versus COP in advanced low-grade non-Hodgkin’s lymphoma – results of a randomized multicenter trial [abstract]Ann Oncol10Suppl 312510076735

 PubMed Web of Science ®Google Scholar

KathRHöffkenKMerkleK2000Prevention of immunological complications in bendamustine treatment [abstract]Onkologie23171

 Google Scholar

HeckHKPreissJMSchmidtP1998Bendamustine (B) and mitoxantrone (M) in the treatment of low grade non-Hodgkin’s lymphoma (NHL) [abstract]J Cancer Res Clin Oncol124SupplR147

 Google Scholar

KahlCHeroldMHöffkesH1997Bendamustine, methotrexate, mitoxantrone and prednisone (BMMP) for the treatment of high grade non-Hodgkin’s lymphomaOnkologie204068

 Web of Science ®Google Scholar

KönigUJunghassCDeckerS1999Response of refractory and relapsed low grade non-Hodgkin’s lymphoma and chronic lymphocytic leukemia to Dexa-BID, a bendamustine hydrochloride-containing regimen [abstract]Ann Oncol10Suppl 3132

 Google Scholar

RuffertK1999Therapy of low grade non-Hodgkin’s lymphoma (NHL) with bendamustine and oral etoposide [abstract]Ann Oncol10Suppl 312510076735

 PubMed Web of Science ®Google Scholar

KönigsmannMKnaufWHeroldM2004Fludarabine and bendamustine in refractory and relapsed indolent lymphoma – a multicenter phase I/II trial of the east german society of hematology and oncology (OSHO)Leuk Lymphoma451821715223642

 PubMed Web of Science ®Google Scholar

KirchnerHHGaedeBSteinhauerEU2001Chemoimmuno-therapy with Fludarabine, Bendamustine and Rituximab for relapsed low grade malignant non-Hodgkin’s lymphoma [abstract]Blood98568

 Web of Science ®Google Scholar

WeideRPandorfAHeymannsJ2004Bendamustine/Mitoxantrone/ Rituximab (BMR): A very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot studyLeuk Lymphoma452445244915621757

 PubMed Web of Science ®Google Scholar

RummelMJAl-BatranSEKimSZ2005Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low – grade non Hodgkin’s lymphomaJ Clin Oncol233383915908650

 PubMed Web of Science ®Google Scholar

RobinsonKSWilliamsMECohenP2005Bendamustine HCl (TREANDATM) treatment in combination with rituximab results in objective responses in patients with refractory/relapsed indolent B-cell and mantle cell non-Hodgkin’s lymphoma: Results from phase II multicenter study (SDX-105–02) [abstract]Blood106923

 Web of Science ®Google Scholar

Van der JagtRHCohenPChesonBD2006Phase II Results of bendamustine in combination with rituximab in relapsed indolent and mantle-cell non-Hodgkin’s lymphoma [abstract]Blood1082710

 Web of Science ®Google Scholar

WeideRHessGKöpplerH2007High anti – lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A mul-ticenter phase II study of the German Low Grade Lymphoma Study Group (GLSG)Leuk Lymphoma48129930617613757

 PubMed Web of Science ®Google Scholar